Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease

• Published in: International journal of molecular sciences Vol. 23; no. 13; p. 7280
• Main Authors: Ramanathan, Raghu, Ali, Ahmad Hassan, Ibdah, Jamal A.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30.06.2022; MDPI
• Subjects: Alcohol use; Body fat; Diabetes; Diet; Drug development; Fatty acids; Fatty liver; Insulin resistance; Lipids; Liver cancer; Liver cirrhosis; Liver diseases; Microbiota; Obesity; Oxidative stress; Pathogenesis; Proteins; Review; Risk factors; Triglycerides; United States > US
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23137280

Nonalcoholic fatty liver disease (NAFLD) is a global pandemic that affects one-quarter of the world’s population. NAFLD includes a spectrum of progressive liver disease from steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis and can be complicated by hepatocellular carcinoma. It is strongly associated with metabolic syndromes, obesity, and type 2 diabetes, and it has been shown that metabolic dysregulation is central to its pathogenesis. Recently, it has been suggested that metabolic- (dysfunction) associated fatty liver disease (MAFLD) is a more appropriate term to describe the disease than NAFLD, which puts increased emphasis on the important role of metabolic dysfunction in its pathogenesis. There is strong evidence that mitochondrial dysfunction plays a significant role in the development and progression of NAFLD. Impaired mitochondrial fatty acid oxidation and, more recently, a reduction in mitochondrial quality, have been suggested to play a major role in NAFLD development and progression. In this review, we provide an overview of our current understanding of NAFLD and highlight how mitochondrial dysfunction contributes to its pathogenesis in both animal models and human subjects. Further we discuss evidence that the modification of mitochondrial function modulates NAFLD and that targeting mitochondria is a promising new avenue for drug development to treat NAFLD/NASH.